Globally, cancer remains one of the most challenging health issues that requires constant advancements in medical treatments. Selpercatinib supplied as 40 mg and 80 mg for oral use under brand Retevmo is one such breakthrough medication, offering new hope for patients with certain specific types of cancer.
What is Selpercatinib (Retevmo): It is a targeted therapy drug developed by Eli Lilly and Company. This therapeutic drug is specifically designed to treat cancers that have alterations in the RET gene, including non-small cell lung cancer (NSCLC), medullary thyroid cancer (MTC), other types of thyroid cancers, and locally advanced or metastatic solid tumors. Approved by the U.S. Food and Drug Administration (FDA) in May 2020, this medicine has shown significant promise in treating these cancer types, offering a new line of defense for patients.
How Does it Work: Retevmo 40 mg/80 mg works by targeting and inhibiting the activity of RET proteins, which play a crucial role in the progression and proliferation of cancer cells. By blocking these proteins, this medication helps slow down or block the progression of tumors with specific RET gene mutations or fusions. This targeted approach ensures that the medicine affects cancer cells more precisely, potentially reducing unwanted damage to normal, healthy cells.
The Need for Selpercatinib in SAARC Countries
The SAARC (South Asian Association for Regional Cooperation) comprises Afghanistan, Bangladesh, Bhutan, India, Maldives, Pakistan, Nepal, and Sri Lanka. These countries face significant healthcare challenges, including the rising incidence of cancer. Access to advanced cancer medicines like Retevmo is critical in these regions to enhance patient outcomes and improve quality of life (QoL).
- Afghanistan: Limited access to specialized cancer medicines necessitates the availability of targeted therapies like Retevmo in Afghanistan.
- Bangladesh: With a growing cancer burden, Bangladesh requires access to cutting-edge therapies to address the requirements of its population.
- Bhutan: Small population but with cancer cases on the rise, Bhutan requires reliable access to promising cancer therapies.
- India: As the largest country in the SAARC region, India has a significant number of cancer patients who can benefit from Retevmo.
- Maldives: Limited healthcare infrastructure means there is a critical need for advanced cancer therapies.
- Nepal: Geographic and economic barriers make access to innovative cancer therapies essential.
- Pakistan: High cancer rates and limited access to modern therapies necessitate the availability of Retevmo in Pakistan.
- Sri Lanka: Rising cancer incidence and the need for advanced therapies to improve patient outcomes.
The Importance of Retevmo in Gulf Countries
The Gulf Cooperation Council (GCC) countries, including Bahrain, Kuwait, Oman, Qatar, Saudi Arabia, and the UAE, also witnessed an increase in cancer cases. These countries have advanced healthcare systems but still face challenges in accessing the latest cancer treatments.
- Bahrain: With a growing healthcare sector, access to oral Retevmo can enhance cancer care.
- Kuwait: Advanced healthcare infrastructure but needs continued access to innovative cancer treatments.
- Oman: Rising cancer rates necessitate access to effective therapies like Retevmo in Oman.
- Qatar: Advanced medical facilities can benefit from the inclusion of Retevmo in their cancer treatment protocols.
- Saudi Arabia: As the largest GCC country, it requires access to a wide range of cancer therapies.
- United Arab Emirates: With world-class healthcare facilities, the inclusion of Retevmo in the UAE can significantly impact cancer care.
Accessibility of Retevmo in India: A City-wise Perspective
Major Metros: In major metro Indian cities like Mumbai, Delhi, Bengaluru, Chennai, Kolkata, Hyderabad Pune, and Ahmedabad, where advanced healthcare facilities are available, Retevmo offers a critical new option for oncologists and their patients. These urban centers are well-equipped to handle the logistics of administering this targeted therapy, ensuring that patients receive timely and effective treatment.
Tier-2 and Tier-3 Cities: Expanding the availability of Retevmo to tier-2 (Jaipur, Lucknow, Kanpur, Nagpur, Indore, Bhopal, Visakhapatnam, Patna) and tier-3 cities (Varanasi, Kochi, Bhubaneswar, Amritsar, Cuttack, Dehradun, Aurangabad, Jamshedpur) is equally important. With the increasing incidence of cancer in smaller cities, ensuring that patients in these areas have access to advanced treatments like Retevmo can significantly impact overall cancer care in India. Ensuring the availability of Retevmo in India can bridge the gap in cancer care.
How Indian Pharma Network (IPN) Facilitate the Supply of Retevmo?
Indian Pharma Network (IPN) plays a crucial role in bridging the gap between advanced cancer therapies and patients in need across SAARC countries, Gulf countries, and India’s cities. Here’s how IPN facilitates the legal supply of Retevmo 40 mg/80 mg:
- Reliable Sourcing: With its extensive network, IPN sources Retevmo directly from manufacturers, ensuring authenticity and quality.
- Regulatory Compliance: IPN navigates the complex regulatory landscapes of different countries to ensure that the therapeutic drug is imported and distributed in compliance with local laws.
- Efficient Distribution: With a robust distribution network, IPN ensures timely delivery of the drug Retevmo to healthcare facilities across SAARC and Gulf countries, as well as all major cities in India.
- Healthcare Partnerships: By collaborating with leading hospitals and healthcare providers, IPN ensures that Retevmo is readily available to oncologists and patients, enhancing treatment options and outcomes.
Conclusion:
The availability of Selpercatinib (Retevmo) in SAARC countries, Gulf countries, and India is crucial for improving cancer treatment outcomes. Indian Pharma Network (IPN) plays an essential role in facilitating the legal supply of this life-saving medication, ensuring that patients across these regions have access to the latest and most effective cancer therapies. By bridging the gap between advanced treatments and those in need, IPN is making a significant impact on the lives of cancer patients and their families across the world.
What is Retevmo used for?
Retevmo (selpercatinib) is used to treat certain types of cancers that have specific alterations in the RET gene, including non-small cell lung cancer (NSCLC), medullary thyroid cancer (MTC), advanced or metastatic thyroid cancer, and advanced or metastatic solid tumors.
How can I obtain Retevmo in my country?
You can obtain Retevmo through the Indian Pharma Network (IPN). Contact IPN via Call/WhatsApp: +91 9310090915 or dial TOLL-FREE: 1800-889-1064 for guidance on the process and to ensure legal and quality-assured access to the medicine.
Is the supply of Retevmo by the Indian Pharma Network (IPN) legal?
Yes, IPN ensures that all supplies of Retevmo are legal and comply with the regulatory requirements of the respective countries.
What makes IPN a reliable supplier?
IPN has a robust distribution network, regulatory expertise, competitive pricing, and quality assurance protocols, making us a trusted partner for healthcare providers and patients.
Does IPN supply Retevmo to all cities in India?
Yes, IPN facilitates the supply of Retevmo to all cities in India, including major metropolitan areas and smaller cities.
Cities in India: Delhi, Mumbai, Kolkata, Chennai, Bangalore, Hyderabad, Ahmedabad, Pune, Surat, Jaipur, Lucknow, Kanpur, Nagpur, Visakhapatnam, Bhopal, Patna, Ludhiana, Agra, Nashik, Faridabad, Vijayawada Meerut, Goa, Rajkot, Varanasi, Srinagar, Amritsar, Allahabad, Ranchi, Howrah, Jabalpur, Gwalior, Jodhpur, Raipur, Kota, Guwahati, Chandigarh, Thiruvananthapuram, Mysore, and more.
How does IPN ensure the quality of Retevmo?
IPN sources Retevmo directly from authorized manufacturers and distributors, maintaining strict quality assurance processes to ensure the medicine’s authenticity and efficacy.
Can IPN provide patient support for Retevmo?
Yes, IPN offers comprehensive patient support services, including information on medication price, and availability, and addressing patient queries.
How does IPN manage the supply chain for Retevmo?
IPN has established a reliable supply chain that includes proper storage, timely transportation, and efficient distribution to ensure the continuous availability of Retevmo.
Can healthcare providers collaborate with IPN?
Yes, IPN actively collaborates with healthcare providers, hospitals, and clinics to streamline the supply process and ensure timely access to Retevmo.
